Want to join the conversation?
$HSP Hospira Inc., the prominent provider of injectable drugs & infusion technologies was acquired by Pfizer Inc today. Pfizer anticipates the transaction to be accretive right away to adjusted diluted EPS upon closing, and accretive by $0.10-0.12 per share in the first full year after the close, with further accretion expected thenceforth.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?